Read by QxMD icon Read

Risperidone cognitive functioning

J Zhao, Y Zhang, Y Y Chao, J Ma, Y F Yang, J Y Zhao, Y H Du, W W Li, X Q Song, L X Lü
Objective: To study the impairments of cognitive function in first-episode schizophrenia and the potential effectiveness of risperidone and olanzapine monotherapy on first-episode schizophrenia. Methods: A total of 57 first-episode schizophrenia and 30 healthy controls were assessed at baseline, and patients were assessed again after 8-week antipsychotics therapy. Results: The positive and negative symptom scale (PANSS) reductive ratio between the two groups was similar. At baseline, the performance of schizophrenia patients was significant poor than healthy controls in the four domains of cognitive function (P<0...
October 11, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Ying Yang, Xiaojing Cheng, Qingzhi Xu, Renjun Li, Zengxun Liu, Liping Wang, Yanqing Zhang, Guoqiang Ren, Jintong Liu
Objective: To evaluate the effect of maintenance modified electroconvulsive therapy (MECT) on schizophrenic patients. Methods: From June 2012 to June 2014, 62 patients with schizophrenia, who had recovered from a successful course of acute MECT, were recruited. Thirty-one patients received maintenance MECT and risperidone, as the experimental group. Another 31 patients were enrolled in the control group, and received risperidone only. The effects on cognitive functions, clinical symptoms and relapse rate were determined...
October 2016: Arquivos de Neuro-psiquiatria
Tarek K Rajji, Benoit H Mulsant, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Philip Gerretsen, Wanna Mar, Bruce G Pollock, David C Mamo, Ariel Graff-Guerrero
OBJECTIVES: To assess the impact of reducing the dose of antipsychotics on cognition and dopaminergic D2 receptor availability in the whole striatum, and identify their relationship in patients with schizophrenia aged 50 years or older. DESIGN: Open-label prospective PET [(11)C]-raclopride study. SETTING: A tertiary care center outpatient setting. PARTICIPANTS: Thirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months...
August 2, 2016: American Journal of Geriatric Psychiatry
Nils Eiel Steen, Monica Aas, Carmen Simonsen, Ingrid Dieset, Martin Tesli, Mari Nerhus, Erlend Gardsjord, Ragni Mørch, Ingrid Agartz, Ingrid Melle, Torill Ueland, Olav Spigset, Ole A Andreassen
OBJECTIVES: Antipsychotics are effective in treating psychosis and mood episodes; however, the effect on cognition is less known. We investigated the association between serum levels of second generation antipsychotics (SGAs) and cognitive performance in psychosis spectrum disorders in a naturalistic setting. METHODS: A total of n = 495 patients with a DSM-IV Schizophrenia and Other Psychotic Disorders (SCZ, n = 373) or Bipolar Disorder (BD, n = 122) diagnosis treated with olanzapine, quetiapine, aripiprazole or risperidone were tested neuropsychologically with concurrent measurement of the serum concentration of the drug...
October 7, 2016: World Journal of Biological Psychiatry
Isabella Pacchiarotti, Jordi León-Caballero, Andrea Murru, Norma Verdolini, Maria Antonietta Furio, Corinna Pancheri, Marc Valentí, Ludovic Samalin, Eva Solé Roigé, Ana González-Pinto, Jose Manuel Montes, Antonio Benabarre, Jose Manuel Crespo, Consuelo de Dios Perrino, Jose Manuel Goikolea, Luis Gutiérrez-Rojas, André F Carvalho, Eduard Vieta
Breast milk is considered the best source of nutrients and provides much better protection than immune modified milk. However, the postpartum period is a phase of increased risk for all women to experience psychiatric symptoms and recurrences or new episodes of bipolar disorder (BD), especially in those who have discontinued treatment. This is a systematic review of the risks and benefits of mood stabilizers and antipsychotics during breastfeeding as they relate to the health and well-being of mothers and their infants...
October 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Mireia Rabella, Eva Grasa, Iluminada Corripio, Sergio Romero, Miquel Àngel Mañanas, Rosa M Antonijoan, Thomas F Münte, Víctor Pérez, Jordi Riba
BACKGROUND: Schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder characterized by odd or bizarre behavior, strange speech, magical thinking, unusual perceptual experiences, and social anhedonia. Schizophrenia proper has been associated with anomalies in dopaminergic neurotransmission and deficits in neurophysiological markers of self-monitoring, such as low amplitude in cognitive event-related brain potentials (ERPs) like the error-related negativity (ERN), and the error positivity (Pe)...
2016: NeuroImage: Clinical
Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti, Toshihiko Kinoshita
BACKGROUND: Recently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia. METHODS: In this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group...
2016: BMC Psychiatry
Randall Phelps, Anne Tsai, Arlene Hagen, Joseph Pinter, Raegan Smith, Martin T Stein
Isela is an 11-year-old Mexican-American girl with mild intellectual disability. During a vacation with her family, she went swimming with dolphins. A few days later, Isela awoke at night with laughing spells; during the day, she was pacing, aggressive, and had a decline in self-care and communication skills. Her parents attributed the symptoms to the dolphins. She was evaluated by a pediatric neurologist. The sleep-deprived electroencephalogram, brain magnetic resonance imaging, lumbar puncture, and thyroid function tests were normal...
May 2016: Journal of Developmental and Behavioral Pediatrics: JDBP
Alwyn M Castelino, Jairam K Ramakrishnan
OBJECTIVE: We aim to determine psychiatrists' identified factors associated with suitability of discharging patients on long-acting injectable antipsychotics (LAI) from specialist to primary care. METHOD: We undertook a retrospective observational study utilising case file reviews. A questionnaire was developed specifically for this including sociodemographic information, clinical characteristics of the patients and clinical opinion on suitability of discharge to primary care...
June 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
Henrik Nørbak-Emig, Bjørn H Ebdrup, Birgitte Fagerlund, Claus Svarer, Hans Rasmussen, Lars Friberg, Peter N Allerup, Egill Rostrup, Lars H Pinborg, Birte Y Glenthøj
BACKGROUND: We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-naïve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms. METHODS: Twenty-five antipsychotic-naïve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI...
May 2016: International Journal of Neuropsychopharmacology
Yosuke Koshikawa, Yoshiteru Takekita, Masaki Kato, Shiho Sakai, Ai Onohara, Naotaka Sunada, Keiichiro Nishida, Masafumi Yoshimura, Chiara Fabbri, Alessandro Serretti, Toshihiko Kinoshita
PURPOSE: The aim of this study was to compare the effects of risperidone long-acting injection (RLAI) and paliperidone palmitate (PP) on non-acute-phase social functioning in patients with schizophrenia. PATIENTS AND METHODS: In this 6-month pilot, open-label, randomized controlled study, 30 patients with schizophrenia who had been treated with RLAI were randomly allocated to the RLAI continuation group or switched to the PP group. Patients were evaluated at baseline and 6 months with the Social Functioning Scale (SFS) as the primary outcome variable and University of California San Diego Performance-Based Skills Assessment Brief (UPSA-B), Social Emotional Cognition Task (SECT), Positive and Negative Syndrome Scale (PANSS), and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores as secondary outcomes...
2016: Neuropsychobiology
Kun Wang, Chengwen Li, Jihong Shi, Hongtu Wei
OBJECTIVE: To explore the effect of patient-controlled intravenous analgesia (PCIA) with dexmedetomidine and sufentanil on early postoperative cognition in elderly patients after spine surgery. METHODS: One hundred fifty-two patients aged more than 60 yr with ASA I-III undergoing elective spine surgery were randomly assigned into two groups: Group S received PCIA with only sufentanil (n=77); Group D received PCIA with dexmedetomidine and sufentanil (n=75). The severity of pain at rest and upon movement was measured at 1, 2, 6, 12, 24 and 48 h after surgery using the 11-point numerical rating scale (NRS)...
August 11, 2015: Zhonghua Yi Xue za Zhi [Chinese medical journal]
S Kedracka-Krok, B Swiderska, U Jankowska, B Skupien-Rabian, J Solich, M Dziedzicka-Wasylewska
The complex network of anatomical connections of the nucleus accumbens (NAc) makes it an interface responsible for the selection and integration of cognitive and affective information to modulate appetitive or aversively motivated behaviour. There is evidence for NAc dysfunction in schizophrenia. NAc also seems to be important for antipsychotic drug action, but the biochemical characteristics of drug-induced alterations within NAc remain incompletely characterized. In this study, a comprehensive proteomic analysis was performed to describe the differences in the mechanisms of action of clozapine (CLO) and risperidone (RIS) in the rat NAc...
March 1, 2016: Neuroscience
Jo C Neill, Ben Grayson, Béla Kiss, István Gyertyán, Paul Ferguson, Nika Adham
Negative symptoms and cognitive impairment associated with schizophrenia are strongly associated with poor functional outcome and reduced quality of life and remain an unmet clinical need. Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. The aim of this study is to evaluate effects of cariprazine in an animal model of cognitive deficit and negative symptoms of schizophrenia...
January 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Felix-Martin Werner, Rafael Coveñas
Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipolar disorder. Like risperidone, cariprazine improves positive and negative schizophrenic symptoms, and ameliorates cognitive functions. Cariprazine induces extrapyramidal symptoms less often than risperidone and can cause acute akathisia...
2015: Therapeutics and Clinical Risk Management
Robin Emsley, Laila Asmal, Stéfan du Plessis, Bonginkosi Chiliza, Martin Kidd, Jonathan Carr, Matthijs Vink
BACKGROUND: Studies of pre-and post-treatment striatal volume in schizophrenia have reported conflicting results. MATERIALS AND METHODS: We assessed dorsal striatal (caudate and putamen) volumes bilaterally in 22 never-treated, non-substance-abusing patients with first-episode schizophrenia or schizophreniform disorder and 23 healthy controls matched for age, sex and educational status. Patients received either risperidone or flupenthixol long acting injection and were compared by structural MRI with controls at weeks 0, 4 and 13...
December 2015: Schizophrenia Research
Joey W Trampush, Todd Lencz, Pamela DeRosse, Majnu John, Juan A Gallego, Georgios Petrides, Youssef Hassoun, Jian-Ping Zhang, Jean Addington, Charles H Kellner, Mauricio Tohen, Katherine E Burdick, Terry E Goldberg, John M Kane, Delbert G Robinson, Anil K Malhotra
First-episode schizophrenia (FES) spectrum disorders are associated with pronounced cognitive dysfunction across all domains. However, less is known about the course of cognitive functioning, following the first presentation of psychosis, and the relationship of cognition to clinical course during initial treatment. The present longitudinal study examined the magnitude of neurocognitive impairment, using the MATRICS Consensus Cognitive Battery, in patients experiencing their first episode of psychosis at baseline and after 12 weeks of randomized antipsychotic treatment with either aripiprazole or risperidone...
November 2015: Schizophrenia Bulletin
Giuseppe D'Agostino, Claudia Cristiano, David J Lyons, Rita Citraro, Emilio Russo, Carmen Avagliano, Roberto Russo, Giuseppina Mattace Raso, Rosaria Meli, Giovambattista De Sarro, Lora K Heisler, Antonio Calignano
BACKGROUND/OBJECTIVES: Nuclear peroxisome proliferator activated receptor-α (PPAR-α) plays a fundamental role in the regulation of lipid homeostasis and is the target of medications used to treat dyslipidemia. However, little is known about the role of PPAR-α in mouse behavior. METHODS: To investigate the function of Ppar-α in cognitive functions, a behavioral phenotype analysis of mice with a targeted genetic disruption of Ppar-α was performed in combination with neuroanatomical, biochemical and pharmacological manipulations...
July 2015: Molecular Metabolism
Kenneth L Subotnik, Laurie R Casaus, Joseph Ventura, John S Luo, Gerhard S Hellemann, Denise Gretchen-Doorly, Stephen Marder, Keith H Nuechterlein
IMPORTANCE: Long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with schizophrenia. However, long-acting medications are rarely used following a first episode of schizophrenia. OBJECTIVE: To compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial performed at a university-based research clinic, between 2005 and 2012...
August 2015: JAMA Psychiatry
Yu-Yin Yang, Chao-Lin Lu, Shih-Mao Lo, Chia-Ho Peng, Yia-Ping Liu
Schizophrenia is a major mental disorder in which patients' cognitive functions gradually deteriorate. Pharmacological intervention with antipsychotics has proven effective, yet it is still debatable whether to initiate treatment in patients' premorbid stage. Based on the developmental origins of schizophrenia, we hypothesize that for those who are at high risk for schizophrenia, particularly with gating problems, an early pharmacological intervention would be beneficial. We performed a pilot rodent study to evaluate this hypothesis...
September 2015: Medical Hypotheses
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"